Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00333437 · ClinicalTrials.gov registry record · NA

Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement

A NA study, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
7
Enrollment target

NCT00333437 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 7 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00333437, a NA study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
7 participants
Enrollment target

Study Summary

Researchers from the Division of Pulmonary and Critical Care Medicine at University of California, San Francisco (UCSF) are conducting a study to evaluate whether mycophenolate mofetil (an immunosuppressive medication, trade named CellCept) is safe and effective for preventing the lung damage from scleroderma from getting worse.

Interventions

  • DRUG Mycophenolate mofetil

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2006-05
Est. Completion 2009-01
Phase NA

What the Registry Record Tells You About NCT00333437

The ClinicalTrials.gov registry entry for NCT00333437 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Mycophenolate mofetil is the first listed.

NCT00333437 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00333437 about?

NCT00333437 is a clinical study titled "Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement". Researchers from the Division of Pulmonary and Critical Care Medicine at University of California, San Francisco (UCSF) are conducting a study to evaluate whether mycophenolate mofetil (an immunosuppressive medication, trade named CellCept) is safe and effective for preventing the lung damage from s...

What is the current status of trial NCT00333437?

This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2006-05. Estimated completion is 2009-01.

What interventions are being tested in trial NCT00333437?

The interventions under investigation include: Mycophenolate mofetil (DRUG).

Who is sponsoring clinical trial NCT00333437?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.